{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:40:08Z","timestamp":1793796008072,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ARMIRO24G0"],"award-info":[{"award-number":["ARMIRO24G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007571","name":"Fondazione Cassa di Risparmio di Civitavecchia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["2-2024"],"award-info":[{"award-number":["2-2024"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["10\/2021"],"award-info":[{"award-number":["10\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MR1-2023-12378412"],"award-info":[{"award-number":["PNRR-MR1-2023-12378412"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5M-2019-23680413"],"award-info":[{"award-number":["5M-2019-23680413"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T02:27:16Z","timestamp":1763519236000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exposure of dams to Elexacaftor\/ Tezacaftor\/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-5603","authenticated-orcid":false,"given":"Angelica","family":"Squarzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3746-791X","authenticated-orcid":false,"given":"Gaia","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine Mandrup","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Serani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Milandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-591X","authenticated-orcid":false,"given":"Roberto","family":"Mandrioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9310-4957","authenticated-orcid":false,"given":"Michele","family":"Protti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mercolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3150-0302","authenticated-orcid":false,"given":"Caterina","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0729-7268","authenticated-orcid":false,"given":"Giovanna","family":"Capodivento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2496-2701","authenticated-orcid":false,"given":"Tiziano","family":"Bandiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benfenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-3953","authenticated-orcid":false,"given":"Lucilla","family":"Nobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Bertorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-8755","authenticated-orcid":false,"given":"Andrea","family":"Armirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcf.2025.11.004_bib0001","first-page":"19","article-title":"Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis","author":"Aspinall","year":"2022","journal-title":"Int J Env Res Public Health"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.004_bib0002","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27382","article-title":"Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Experiences at a Quaternary CF Care Center","volume":"60","author":"Papadakis","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.004_bib0004","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.04.012","article-title":"The combination elexacaftor\/tezacaftor\/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner","author":"Liessi","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.004_bib0006","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcf.2024.05.004","article-title":"Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)","volume":"23","author":"Ciobanu","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.004_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.plipres.2011.12.002","article-title":"Dihydroceramide desaturase and dihydrosphingolipids: debutant players in the sphingolipid arena","volume":"51","author":"Fabrias","year":"2012","journal-title":"Prog Lipid Res"},{"issue":"10","key":"10.1016\/j.jcf.2025.11.004_bib0008","first-page":"133","article-title":"Sphingolipid desaturase DEGS1 is essential for mitochondria-associated membrane integrity","author":"Planas-Serra","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2025.11.004_bib0010","unstructured":"EMA KAFTRIO - EPAR Medicine Overview. 2022."},{"key":"10.1016\/j.jcf.2025.11.004_bib0011","first-page":"10","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","author":"Ripani","year":"2023","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.jcf.2025.11.004_bib0012","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1194\/jlr.P094433","article-title":"Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway","volume":"60","author":"Blackburn","year":"2019","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.jcf.2025.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41431-019-0444-z","article-title":"DEGS1 variant causes neurological disorder","volume":"27","author":"Dolgin","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.004_bib0014","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI124159","article-title":"DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans","volume":"129","author":"Karsai","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.004_bib0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1172\/JCI123959","article-title":"Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy","volume":"129","author":"Pant","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0016","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1038\/s41598-017-08314-1","article-title":"Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies","volume":"7","author":"Capodivento","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.004_bib0017","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1194\/jlr.RA120000627","article-title":"Dynamics of sphingolipids and the serine palmitoyltransferase complex in rat oligodendrocytes during myelination","volume":"61","author":"Davis","year":"2020","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019849","article-title":"Oligodendrocytes as Regulators of Neuronal Networks during Early Postnatal Development","volume":"6","author":"Doretto","year":"2011","journal-title":"Plos One"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.004_bib0019","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF00968708","article-title":"Myelination in the developing human brain: Biochemical correlates","volume":"19","author":"Kinney","year":"1994","journal-title":"Neurochem Res"},{"key":"10.1016\/j.jcf.2025.11.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101236","article-title":"The pathophysiological role of dihydroceramide desaturase in the nervous system","volume":"91","author":"Tzou","year":"2023","journal-title":"Prog Lipid Res"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nchembio.1114","article-title":"Identification of DES1 as a vitamin A isomerase in Muller glial cells of the retina","volume":"9","author":"Kaylor","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jcf.2025.11.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09156-3","article-title":"The development of synaptic transmission is time-locked to early social behaviors in rats","volume":"10","author":"Naskar","year":"2019","journal-title":"Nat Commun"},{"issue":"W1","key":"10.1016\/j.jcf.2025.11.004_bib0024","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.1093\/nar\/gky310","article-title":"MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis","volume":"46","author":"Chong","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.jcf.2025.11.004_bib0025","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.004_bib0026","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.004_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS\/MS Method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcf.2025.11.004_bib0028","first-page":"236","article-title":"Volumetric absorptive microsampling for the therapeutic drug monitoring of psychiatric patients treated with cariprazine","author":"Mill\u00e1n-Santiago","year":"2023","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/YIC.0000000000000503","article-title":"Microsampling for therapeutic drug monitoring in psychiatric practice","volume":"39","author":"Protti","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.004_bib0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/pharmaceutics17020200","article-title":"A Novel LC-MS\/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices","volume":"17","author":"Pigliasco","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.004_bib0031","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/FTD.0000000000001231","article-title":"Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS\/MS","volume":"46","author":"Vonk","year":"2024","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcf.2025.11.004_bib0032","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: An observational study","volume":"236","author":"Christina","year":"2025","journal-title":"Respir Med"},{"issue":"16","key":"10.1016\/j.jcf.2025.11.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138722","article-title":"Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta","volume":"5","author":"Liessi","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.jcf.2025.11.004_bib0034","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","article-title":"Carnitine transport and fatty acid oxidation","volume":"1863","author":"Longo","year":"2016","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"10.1016\/j.jcf.2025.11.004_bib0035","first-page":"132","article-title":"The associations between prenatal plastic phthalate exposure and lipid acylcarnitine levels in humans and mice","author":"Vacy","year":"2025","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0036","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/toxsci\/kfae094","article-title":"The brominated flame retardant hexabromocyclododecane causes systemic changes in polyunsaturated fatty acid incorporation in mouse lipids","volume":"203","author":"Kramer","year":"2025","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.004_bib0037","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1002\/cpz1.135","article-title":"SHIRPA as a Neurological Screening Battery in Mice","volume":"1","author":"Lalonde","year":"2021","journal-title":"Curr Protoc"},{"issue":"1-2","key":"10.1016\/j.jcf.2025.11.004_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3940(01)01885-7","article-title":"SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice","volume":"306","author":"Rogers","year":"2001","journal-title":"Neurosci Lett"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.004_bib0039","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jacbts.2019.07.004","article-title":"CFTR Therapeutics Normalize Cerebral Perfusion Deficits in Mouse Models of Heart Failure and Subarachnoid Hemorrhage","volume":"4","author":"Lidington","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"10.1016\/j.jcf.2025.11.004_bib0040","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.004_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2024.11.014","article-title":"Lens-related ocular changes in fetal rats following in-utero exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Zhu","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:32Z","timestamp":1778822072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325025007"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure of dams to Elexacaftor\/ Tezacaftor\/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}